The Department of Health and Human Services (HHS) is moving away from its long-standing commitment to contraceptive access. Under the Trump administration, federal family planning priorities are shifting significantly. Instead of expanding birth control availability, the government now appears focused on fertility awareness, pronatalist goals, and what it calls “natural family planning.” This change affects millions of low-income women who depend on federally funded health programs.
What Is Changing in HHS Contraceptive Policy?
For more than five decades, Title X has served as the federal government’s only dedicated family planning program. Originally signed into law by President Richard Nixon in 1970, it provided low-income women with access to contraception, STI screenings, and other reproductive health services — regardless of ability to pay. At its peak, the program served over five million patients annually.
Today, however, the program’s direction has shifted sharply. In early April 2025, HHS invited nonprofits to apply for Title X grants for fiscal year 2027. The 67-page Notice of Funding Opportunity mentioned contraception just once — describing it negatively as overprescribed, burdened with side effects, and representative of an “overreliance on pharmaceutical and surgical treatments.”
This marks a dramatic departure from Title X’s founding mission. Consequently, health advocates and medical professionals across the country are raising alarms.
Title X: A Program Built on Contraceptive Access
Decades of bipartisan support built Title X into a cornerstone of women’s health. When Nixon signed the legislation, he framed it as a tool to help families determine the number and spacing of their children. Over time, the program expanded to include fertility services, breast and cervical cancer screenings, and STI treatment.
Furthermore, Title X served a critical equity function. It specifically targeted women who could not afford private reproductive health care. As a result, it reduced unintended pregnancies and improved health outcomes for millions of low-income Americans.
Moreover, the program commanded bipartisan respect for its direct, evidence-based approach. That consensus now appears fractured under the current administration.
The New 2027 Funding Guidelines Explained
The revised Title X guidelines represent a fundamental reorientation of the program. Rather than prioritizing contraceptive access, the new framework emphasizes fertility, family formation, and reproductive health conditions such as polycystic ovary syndrome (PCOS), endometriosis, low testosterone, and erectile dysfunction.
Additionally, the guidelines state that Title X will continue to help women “achieve healthy pregnancies.” However, they do not explicitly reference preventing unintended pregnancies — a core goal of the program for more than 50 years.
HHS also announced plans to make up to $257 million available through Title X for 2027. This represents a decrease from the roughly $286 million the program received annually over the past decade. Therefore, clinics must do more with less — while also pivoting their programmatic focus.
Why “Natural Family Planning” Raises Concerns
The new guidelines push clinics toward “natural family planning” — a method that involves tracking menstrual cycles to identify and avoid fertile windows. This approach is significantly less effective at preventing pregnancy than hormonal contraception. Nevertheless, the administration expects Title X applicants to “demonstrate how their projects will integrate noninvasive, evidence-based practices that promote health literacy, fertility awareness, and reproductive health without unnecessary medicalization.”
Decades of research confirm that hormonal birth control is safe for most people. Serious complications remain rare. While some studies identify a slightly elevated risk of breast cancer in long-term pill users, medical consensus overwhelmingly supports hormonal contraception as effective and evidence-based.
How Medicaid Cuts Deepen the Crisis
Funding pressures extend well beyond Title X. In spring 2025, HHS withheld $65.8 million in Title X grants from 20 states after grantees made public statements supporting diversity, equity, and inclusion. This action disrupted services at clinics already operating on tight budgets.
Then, on July 4, 2025, President Trump signed H.R. 1 — a budget reconciliation bill that blocks Medicaid funding for one year to nonprofits primarily engaged in family planning that also provide abortion care. This directly affects all Planned Parenthood clinics and other large family planning providers.
The combined effect of H.R. 1 and the potential expiration of enhanced premium tax credits is projected to leave an estimated 10 million people without health insurance. For many of these individuals, federally funded clinics are their only point of access to contraceptive care.
States with large Medicaid populations — including California, New York, and Kentucky — face the sharpest cuts. Furthermore, federally qualified health centers and rural hospitals that rely on Medicaid reimbursements may be forced to reduce services or close entirely.
What Experts and Advocates Are Saying
Health professionals are speaking out forcefully against these changes. Liz Romer, a former chief clinical adviser for the HHS Office of Population Affairs, warned that there is “not even enough funding to support the core premise of contraception.” She added that expanding Title X’s scope is possible only if the program does not abandon its contraceptive foundation.
Clare Coleman, president and CEO of the National Family Planning and Reproductive Health Association, said tying Title X to birth-rate goals effectively replaces individual reproductive decision-making with a government objective. “That’s not what this program was designed to do,” she noted.
Meanwhile, the American College of Obstetricians and Gynecologists (ACOG) announced it would stop accepting federal funds after changes in funding guidelines conflicted with its ability to provide timely, evidence-based guidance. The decision drew applause from a Trump administration spokesperson — though it leaves a critical gap in national reproductive health standards.
Additionally, a 2024 KFF survey found that eight in ten women of childbearing age reported using some form of contraception in the previous 12 months. That figure underscores how central contraceptive access remains to women’s everyday health decisions.
What This Means for Women Across America
The consequences of this policy shift will be felt unevenly — and urgently. Low-income women, women of color, young women, and those living in rural areas face the greatest risk. These groups already face the largest barriers to private reproductive health care. They depend disproportionately on Title X clinics and Medicaid-funded providers.
Moreover, the administration’s stated goal of boosting the birth rate adds a political dimension to what has historically been a public health program. President Trump has called for “a new baby boom,” and aides have solicited proposals ranging from baby bonuses to expanded fertility planning. Critics argue this pronatalist agenda should not come at the cost of individual reproductive autonomy.
Meanwhile, the US fertility rate continues to fall. The CDC reported 3.6 million births in 2025 — a 1% decline from 2024 — with the fertility rate dropping 23% since 2007. Whether restricting contraceptive access will reverse this trend remains deeply contested among demographers and public health experts.
Clinics are still working through the new guidelines to assess how they will affect day-to-day service delivery. A 2021 regulation requiring Title X projects to offer a broad range of contraceptive methods remains in place — for now. However, the broader policy direction signals a sharp move away from the contraceptive access mission that has defined the program for half a century.
